Rociletinib

Search with Google Search with Bing

Information
Drug Name
Rociletinib
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		D Predictive Supports Resistance Somatic 3 28202511 Detail
lung non-small cell carcinoma EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		B Predictive Supports Sensitivity/Response Somatic 4 25923550 Detail
lung non-small cell carcinoma EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		D Predictive Supports Sensitivity/Response Somatic 3 24065731 Detail
lung non-small cell carcinoma EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		D Predictive Supports Sensitivity/Response Somatic 2 26515464 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Evidence of wild-type allele-mediated resistance, ... EGFR EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a phase1-2 study, patients with the T790M mutat... EGFR EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
CO-1686 (Rociletinib) more effectively induced apo... EGFR EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
For cell harboring EGFR T790M mutation, osimertini... EGFR EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02547675 No longer available Rociletinib (CO-1686) USA Expanded Access Program
NCT02147990 Terminated Phase 2 Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer June 16, 2014 August 27, 2019
NCT02322281 Terminated Phase 3 TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy February 2015 March 29, 2018
NCT01526928 Terminated Phase 1/Phase 2 Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients March 27, 2012 August 27, 2018
NCT02580708 Terminated Phase 1/Phase 2 Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer September 30, 2015 June 27, 2016
NCT02630186 Terminated Phase 1/Phase 2 A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC February 24, 2016 September 5, 2017
NCT02705339 Withdrawn Phase 2 Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) May 2016 April 2020